Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

Mazdutide Dosing Protocol: 5 mg Vial — Week-by-Week Titration & Supplies

Dosing protocol for mazdutide (IBI362, Innovent Biologics) using the 5 mg compounded vial, based on GLORY Phase 3 trial titration data.

Go to peptide profileCalculate your dose

Quickstart highlights

Mazdutide (IBI362) is a weekly GLP-1/glucagon receptor dual agonist developed by Innovent Biologics.

  • Concentration: 5 mg/mL (5 mg vial + 1 mL bacteriostatic water).
  • At 5 mg/mL: 3 mg = 60 units, 4.5 mg = 90 units, 5 mg = 100 units (full vial).
  • GLORY-1 Phase 3: 6 mg weekly dose achieved 14.5% body weight reduction over 36 weeks.
  • The 5 mg vial covers starting (3 mg) and intermediate (4.5 mg) titration phases; use 10 mg vial for 6 mg maintenance.
  • Mazdutide is approved in China for T2DM; not yet FDA-approved in the US.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-8300060Once weekly3 mg starting dose — 60 units; assess GI tolerability over 8 weeks
9-16450090Once weekly4.5 mg — 90 units; intermediate dose if tolerating 3 mg well
17+6000120Once weekly6 mg target maintenance — requires 10 mg vial; one 5 mg vial cannot deliver 6 mg at this concentration

Reconstitution steps

  1. Draw 1 mL bacteriostatic water; inject slowly down the vial wall.
  2. Swirl gently until dissolved; do not shake.
  3. Final concentration: 5 mg/mL. Note: the 6 mg maintenance dose exceeds this vial's 5 mg capacity; use the 10 mg vial for 6 mg+.
  4. Label with date; refrigerate at 2–8 °C immediately.

Supplies needed

8-week plan

  • 2 vials
  • 8 syringes
  • 2 mL bac water
  • 8 alcohol swabs

16-week plan

  • 4 vials
  • 16 syringes
  • 4 mL bac water
  • 16 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Initiate mazdutide GLP-1/glucagon dual agonist protocol at 3 mg and titrate to 4.5 mg using the 5 mg vial before advancing to the 10 mg vial for the 6 mg maintenance phase.

Cycle length: 16 weeks on.

Off-cycle: 8 weeks off; monitor weight and glycemic markers during off-cycle.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted at 5 mg/mL: refrigerate 2–8 °C; use within 28 days. One 5 mg vial provides 1 full dose at 5 mg or ~1.67 doses at 3 mg.

Injection & tracking tips

  • The 5 mg vial supports doses up to 5 mg at 5 mg/mL; for the 6 mg maintenance target, use the 10 mg vial.
  • Rotate injection sites weekly; abdomen is preferred for GLP-1 class peptides.
  • Mazdutide is approved in China for type 2 diabetes; US protocols are for research use only.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Track fasting glucose and HbA1c every 8 weeks for metabolic response assessment.
  • Log GI side effects (nausea, diarrhea) for the first 12 weeks.
  • Record body weight weekly — expect ~14.5% reduction over 36 weeks at 6 mg per GLORY-1 data.
Log your cycle in the calculator →

How this works & references

Mazdutide (IBI362) is a weekly GLP-1/glucagon receptor dual agonist developed by Innovent Biologics. The Phase 3 GLORY-1 trial (NCT05564910) in China showed 14.5% body weight reduction over 36 weeks at 6 mg weekly dose. The GLORY-2 trial targets Chinese patients with BMI ≥27 with comorbidities. Approved in China for T2DM under the trade name Mazdutide; FDA submission pending. Glucagon receptor agonism provides complementary hepatic fat oxidation to GLP-1-mediated appetite suppression.

Sources

Frequently asked questions

Why can't the 5 mg vial cover the 6 mg maintenance dose?
At 5 mg/mL, a 5 mg vial reconstitutes to exactly 1 mL, providing a maximum dose of 5 mg (100 units). The 6 mg target dose requires 1.2 mL at 5 mg/mL concentration — exceeding the vial's content. Use the 10 mg vial for 6 mg+ maintenance.
Is mazdutide available in the US?
Mazdutide is not FDA-approved in the US as of February 2026. It is approved in China for type 2 diabetes. In the US, it is available through compounding pharmacies for research purposes only, with FDA regulatory submission in progress.
How does mazdutide compare to tirzepatide?
Both are dual agonists, but mazdutide targets GLP-1/glucagon receptors while tirzepatide targets GLP-1/GIP receptors. Clinical trial data suggest comparable weight loss (14.5% for mazdutide at 6 mg versus 19.5–20.9% for tirzepatide at 10–15 mg), though direct comparisons are not available.
What side effects are most common with mazdutide?
Nausea (35–45%), vomiting (15–25%), diarrhea (20–30%), and decreased appetite — consistent with the GLP-1/glucagon class profile. GI events peak in weeks 1–8 and decline significantly thereafter.
Is mazdutide WADA-prohibited?
No — mazdutide is not currently on the WADA prohibited list. However, given its GLP-1/glucagon dual agonist mechanism and potential endurance performance effects via metabolic enhancement, this classification may be revisited as Phase 3 data accumulates.

Related protocols

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

View protocol

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

View protocol

Testagen Dosing Protocol: 20 mg Vial — Testicular Bioregulator & Testosterone Support Guide

Testagen (Lys-Glu-Asp-Gly tetrapeptide) Russian testicular bioregulator dosing guide — Leydig cell gene normalization for testosterone production optimization and male reproductive aging support.

View protocol

Prostamax Dosing Protocol: 20 mg Vial — Prostate Bioregulator Guide

Prostamax (Lys-Asp-Glu-Leu tetrapeptide) Russian prostate bioregulator dosing guide — prostatic epithelial gene normalization for BPH, prostate aging, and urinary symptom support.

View protocol

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Browse vetted clinicsView full peptide profile →